Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sumithra Mandrekar

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
American Journal of Hematology|November 10, 2009
Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survivalMartha Q Lacy, Sumithra Mandrekar, Angela Dispenzieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2022
Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for InterventionAndrew Hantel, Jessica Kohlschmidt, Ann-Kathrin Eisfeld, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 27, 2014
NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance statusGrace K Dy, Julian R Molina, Yingwei Qi, et al.
Cancer|April 27, 2005
Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderlySteven E Schild, Philip J Stella, Burke J Brooks, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancerGrace K Dy, James P Thomas, George Wilding, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2005
A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancerGrace K Dy, Laura M Bruzek, Gary A Croghan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2019
RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database AnalysisSaskia Litière, Gaëlle Isaac, Elisabeth G E De Vries, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial dataJulian R Molina, Scott H Kaufmann, Joel M Reid, et al.
European Journal of Cancer (Oxford, England : 1990)|May 31, 2016
RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working GroupLawrence H Schwartz, Lesley Seymour, Saskia Litière, et al.
European Journal of Cancer (Oxford, England : 1990)|May 19, 2016
RECIST 1.1-Update and clarification: From the RECIST committeeLawrence H Schwartz, Saskia Litière, Elisabeth de Vries, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
American Journal of Hematology|November 10, 2009
Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survivalMartha Q Lacy, Sumithra Mandrekar, Angela Dispenzieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2022
Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for InterventionAndrew Hantel, Jessica Kohlschmidt, Ann-Kathrin Eisfeld, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 27, 2014
NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance statusGrace K Dy, Julian R Molina, Yingwei Qi, et al.
Cancer|April 27, 2005
Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderlySteven E Schild, Philip J Stella, Burke J Brooks, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancerGrace K Dy, James P Thomas, George Wilding, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2005
A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancerGrace K Dy, Laura M Bruzek, Gary A Croghan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2019
RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database AnalysisSaskia Litière, Gaëlle Isaac, Elisabeth G E De Vries, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial dataJulian R Molina, Scott H Kaufmann, Joel M Reid, et al.
European Journal of Cancer (Oxford, England : 1990)|May 31, 2016
RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working GroupLawrence H Schwartz, Lesley Seymour, Saskia Litière, et al.
European Journal of Cancer (Oxford, England : 1990)|May 19, 2016
RECIST 1.1-Update and clarification: From the RECIST committeeLawrence H Schwartz, Saskia Litière, Elisabeth de Vries, et al.
Pageof 4